BLU-285, DCC-2618 Show Activity against GIST

  • Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.CD-NB2016-165.
PMID: 28077435 DOI: 10.1158/2159-8290.CD-NB2016-165
Abstract

Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease progression due to activation loop mutations, which are resistant to approved drugs. However, phase I trials suggest that the Cancer is sensitive to two new agents: BLU-285 and DCC-2618. In addition, liquid biopsies, which were used to follow patients during the trials, may be valuable tools in tracking disease progression and assessing tumor heterogeneity.

Products